Posted January 10, 2019 by naveen_pbi
Market by Type (Meningococcal Conjugate Vaccines, Meningococcal Polysaccharide Vaccine, Serogroup B Meningococcal Vaccine) By End user
Meningococcal disease is a fatal disease caused by a bacteria called as Neisseria Meningitides which cause potential infection in the meninges, the thin layers of connective tissues which surrounds spinal cord and brain. Common symptoms are bacteraemia, pneumonia and meningitis associated with neck stiffness, nausea, high fever, vomiting, confusion, rashes and lethargy.
Changing aspects of meningococcal vaccines market
Factors which are playing important role in the growth of meningococcal vaccines are-
•	Increases incidence of meningococcal disease
•	Growing awareness about availability of its vaccines
•	Government based initiatives
•	Increased R & D investments by different players with introduction of advanced vaccines are leading the growth of meningococcal vaccines market.
However, vaccines cost, lack of awareness about the disease and stringent regulatory policies are huge restraints in the global meningococcal vaccines market.
With encouraging government initiatives, the global market for meningococcal diseases is growing at expedited rate. The meningococcal vaccine market has very limited numbers of market players and is expecting a lot of new entries in the near future. With increasing awareness about the disease and availability of vaccine, MenA joined hands with other vaccine programs in Africa to prevent around 123000 deaths in 2018.
In the global meningococcal vaccines market, North America holds the strongest position followed by Europe. Factors such as population surge, increased cases of meningococcal diseases accounts for account share. In Europe, Germany, UK and France hold the largest share due to great healthcare facilities and government bases initiatives. Asia Pacific is showing a substantial growth due to disposable income, different government immunization to eradicate meningococcal diseases.
Read more Insights at https://www.precisionbusinessinsights.com/market-reports/meningococcal-vaccines-market/
Notable market development
TRUMENBA (meningococcal group B vaccine) from Pfizer received approval from US FDA in 2014 to prevent meningococcal vaccine.
Some of the key market players in the global meningococcal vaccines market are-
•	GlaxoSmithKline plc. (UK)
•	JN-International Medical Corporation (U.S.)
•	Novartis International AG (Switzerland)
•	Sanofi (France)
•	Pfizer, Inc. (U.S.)
Avail free sample report at https://bit.ly/2FWDDd8
The global meningococcal vaccines market is divided into following categories-
•	Meningococcal Conjugate Vaccines
•	Meningococcal Polysaccharide Vaccine
•	Serogroup B Meningococcal Vaccine
Issued By Naveen
Tags Meningococcal Vaccines Market	